Update 2018: 18F-FDG PET/CT and PET/MRI in Head and Neck Cancer.

Journal Article (Review;Journal Article)

There are recent advances, namely, a standardized method for reporting therapy response (Hopkins criteria), a multicenter prospective cohort study with excellent negative predictive value of F-FDG PET/CT for N0 clinical neck, a phase III multicenter randomized controlled study establishing the value of a negative posttherapy F-FDG PET/CT for patient management, a phase II randomized controlled study demonstrating radiation dose reduction strategies for human papilloma virus-related disease, and Food and Drug Administration approval of nivolumab for treatment of recurrent head and neck squamous cell carcinoma.

Full Text

Duke Authors

Cited Authors

  • Sanli, Y; Zukotynski, K; Mittra, E; Chen, DL; Nadel, H; Niederkohr, RD; Subramaniam, RM

Published Date

  • December 2018

Published In

Volume / Issue

  • 43 / 12

Start / End Page

  • e439 - e452

PubMed ID

  • 30394934

Electronic International Standard Serial Number (EISSN)

  • 1536-0229

International Standard Serial Number (ISSN)

  • 0363-9762

Digital Object Identifier (DOI)

  • 10.1097/rlu.0000000000002247


  • eng